Free Trial

Orchestra BioMed Q4 2024 Earnings Report

Orchestra BioMed logo
$2.76 -0.35 (-11.25%)
As of 04/4/2025 04:00 PM Eastern

Orchestra BioMed EPS Results

Actual EPS
-$0.43
Consensus EPS
-$0.43
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Orchestra BioMed Revenue Results

Actual Revenue
$0.25 million
Expected Revenue
$0.79 million
Beat/Miss
Missed by -$540.00 thousand
YoY Revenue Growth
N/A

Orchestra BioMed Announcement Details

Quarter
Q4 2024
Time
Before Market Opens

Conference Call Resources

Remove Ads

Orchestra BioMed Earnings Headlines

Your Retirement Is Caught in the Crossfire
When Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. Now… as new tariffs take effect, gold is breaking records again. You've hopefully already seen this in action… but gold is surpassing $3,000 per ounce for the first time EVER.
Orchestra BioMed initiated with a Buy at BTIG
See More Orchestra BioMed Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Orchestra BioMed? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Orchestra BioMed and other key companies, straight to your email.

About Orchestra BioMed

Orchestra BioMed (NASDAQ:OBIO) operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.

View Orchestra BioMed Profile

More Earnings Resources from MarketBeat